ATLANTA--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced it presented preclinical results demonstrating that CTP-221, Concert’s deuterated S-lenalidomide analog, exhibits enhanced potency compared to racemic lenalidomide. Revlimid®, which is marketed for the treatment of multiple myeloma and del(5q) myelodysplastic syndromes, contains racemic lenalidomide as its active pharmaceutical ingredient. The CTP-221 findings were presented in a poster at the American Society of Hematology’s (ASH) 2012 Annual Meeting. Concert expects to complete preclinical testing of CTP-221 and file an Investigational New Drug Application in 2013.
